Rikuto Masuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rikuto Masuda has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Tomoaki Yoshimura
Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Japan
9 shared publications - Yoshihiro Noguchi
Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu-shi 501-1196, Gifu, Japan
9 shared publications Ai Oonishi
Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu-shi, 501-1196, Gifu, Japan
2 shared publicationsEiseki Usami
2 shared publicationsMichio Kimura
2 shared publications- Ryo Kobayashi
Laboratory of Advanced Medical Pharmacy Gifu Pharmaceutical University Gifu Japan
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 586
Risk Stratification and Factors Associated with Heart Failure Hospitalization During Osimertinib Therapy
Background: Osimertinib is the standard of care for epidermal growth factor receptor mutation-positive non-small cell lung cancer, but heart failure hospitalization (HFH) remains a concern, and no practical tool exists to stratify HFH risk during therapy. Methods: In this retrospective cohort study using a Japanese claims database, 5802 patients newly initiating osimertinib were followed for HFH during treatment. Baseline predictors assessed before the index date were selected by 10-fold cross-validated least absolute shrinkage and selection operator (LASSO) logistic regression and internally validated by bootstrapping (B = 500), repeating predictor selection in each resample. Cumulative incidence functions and Fine–Gray models treated death as a competing event; cause-specific Cox models served as sensitivity analyses. Results: HFH occurred in 169 patients (2.9%) during a median on-treatment follow-up of 9.3 months, with 268 competing deaths. LASSO retained seven predictors. The apparent concordance index (C-index) was 0.731 (95% confidence interval, 0.691–0.771) and the optimism-corrected C-index 0.718. Observed incidence increased 10.2-fold across predicted-risk deciles (1.03–10.50%). Fine–Gray and Cox estimates closely matched the logistic model. Conclusions: Baseline cardiovascular vulnerability stratifies HFH risk during osimertinib therapy. The nomogram, not externally validated, is best used as a screening aid to identify patients who may benefit from intensified cardiovascular monitoring.
- 29 September 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (10) , 586
Open AccessRisk Stratification and Factors Associated with Heart Failure Hospitalization During Osimertinib Therapy
Background: Osimertinib is the standard of care for epidermal growth factor receptor mutation-positive non-small cell lung cancer, but heart failure hospitalization (HFH) remains a concern, and no practical tool exists to stratify HFH risk during therapy. Methods: In this retrospective cohort study using a Japanese claims database, 5802 patients newly initiating osimertinib were followed for HFH during treatment. Baseline predictors assessed before the index date were selected by 10-fold cross-validated least absolute shrinkage and selection operator (LASSO) logistic regression and internally validated by bootstrapping (B = 500), repeating predictor selection in each resample. Cumulative incidence functions and Fine–Gray models treated death as a competing event; cause-specific Cox models served as sensitivity analyses. Results: HFH occurred in 169 patients (2.9%) during a median on-treatment follow-up of 9.3 months, with 268 competing deaths. LASSO retained seven predictors. The apparent concordance index (C-index) was 0.731 (95% confidence interval, 0.691–0.771) and the optimism-corrected C-index 0.718. Observed incidence increased 10.2-fold across predicted-risk deciles (1.03–10.50%). Fine–Gray and Cox estimates closely matched the logistic model. Conclusions: Baseline cardiovascular vulnerability stratifies HFH risk during osimertinib therapy. The nomogram, not externally validated, is best used as a screening aid to identify patients who may benefit from intensified cardiovascular monitoring.
- Open Access
- 17 September 2026
- Published by Springer Nature in Drugs - Real World Outcomes
- p. 1-9
Estimated Acquisition Cost Differences between Fixed and Simulated Body Weight-Based Nivolumab Dosing Using Real-World Claims Data in Japan
- 17 September 2026
- Published by Springer Nature in Drugs - Real World Outcomes
- p. 1-9
Open AccessEstimated Acquisition Cost Differences between Fixed and Simulated Body Weight-Based Nivolumab Dosing Using Real-World Claims Data in Japan
- 17 October 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt A) , 120496
Analysis of acute pancreatitis caused by multi-acting receptor-targeted antipsychotics using the Japanese claims database
- 17 October 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt A) , 120496
Analysis of acute pancreatitis caused by multi-acting receptor-targeted antipsychotics using the Japanese claims database
- 13 October 2025
- Published by S. Karger AG in Oncology
- Vol. 104 (6) , 684-694
Sex Differences in Cardiotoxicity of Anaplastic Lymphoma Kinase Inhibitors: An Analysis of the FDA Adverse Event Reporting System
Introduction: Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have transformed the management of ALK-rearranged non-small-cell lung cancer (NSCLC), yet their cardiotoxicity profile remains incompletely characterized, particularly with respect to sex differences. Given the high prevalence of cardiovascular disease in patients with NSCLC, understanding potential sex-specific risks is critical. Methods: We conducted a pharmacovigilance analysis using the US FDA Adverse Event Reporting System (FAERS) database (Q1 2004–Q3 2021) to examine cardiotoxicity signals associated with five ALK-TKIs (alectinib, brigatinib, ceritinib, crizotinib, and lorlatinib). Adverse events were classified using the MedDRA hierarchy, focusing on cardiac disorders. Disproportionality analysis was performed via the Bayesian Confidence Propagation Neural Network (BCPNN) method, calculating Information Component (IC) scores. Sex differences were assessed by computing the IC delta and its 95% confidence interval. Results: Cardiotoxicity signals, particularly heart failure and pericardial disorders, were detected for alectinib, ceritinib, crizotinib, and lorlatinib but not brigatinib. Notably, significant female-specific signals emerged for left ventricular failure with alectinib; pericardial disorders with ceritinib and crizotinib; and heart failure not elsewhere classified (the MedDRA category used for heart failure cases that do not fall into specific classifications) with crizotinib. Conclusion: This is the first study to identify sex differences in ALK-TKI-associated cardiotoxicity, highlighting a consistent female predominance in reported adverse events. In particular, considering its widespread use and the clinical importance of left ventricular failure, the pronounced disproportionality signal of cardiotoxicity in females associated with alectinib is thought to have substantial clinical impact. These results underscore the need for heightened clinical vigilance and further research into sex-specific risk stratification and preventive strategies for cardiotoxicity in patients receiving ALK-TKIs.
- 13 October 2025
- Published by S. Karger AG in Oncology
- Vol. 104 (6) , 684-694
Sex Differences in Cardiotoxicity of Anaplastic Lymphoma Kinase Inhibitors: An Analysis of the FDA Adverse Event Reporting System
Introduction: Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have transformed the management of ALK-rearranged non-small-cell lung cancer (NSCLC), yet their cardiotoxicity profile remains incompletely characterized, particularly with respect to sex differences. Given the high prevalence of cardiovascular disease in patients with NSCLC, understanding potential sex-specific risks is critical. Methods: We conducted a pharmacovigilance analysis using the US FDA Adverse Event Reporting System (FAERS) database (Q1 2004–Q3 2021) to examine cardiotoxicity signals associated with five ALK-TKIs (alectinib, brigatinib, ceritinib, crizotinib, and lorlatinib). Adverse events were classified using the MedDRA hierarchy, focusing on cardiac disorders. Disproportionality analysis was performed via the Bayesian Confidence Propagation Neural Network (BCPNN) method, calculating Information Component (IC) scores. Sex differences were assessed by computing the IC delta and its 95% confidence interval. Results: Cardiotoxicity signals, particularly heart failure and pericardial disorders, were detected for alectinib, ceritinib, crizotinib, and lorlatinib but not brigatinib. Notably, significant female-specific signals emerged for left ventricular failure with alectinib; pericardial disorders with ceritinib and crizotinib; and heart failure not elsewhere classified (the MedDRA category used for heart failure cases that do not fall into specific classifications) with crizotinib. Conclusion: This is the first study to identify sex differences in ALK-TKI-associated cardiotoxicity, highlighting a consistent female predominance in reported adverse events. In particular, considering its widespread use and the clinical importance of left ventricular failure, the pronounced disproportionality signal of cardiotoxicity in females associated with alectinib is thought to have substantial clinical impact. These results underscore the need for heightened clinical vigilance and further research into sex-specific risk stratification and preventive strategies for cardiotoxicity in patients receiving ALK-TKIs.
- 25 September 2025
- Published by S. Karger AG in Oncology
- Vol. 104 (6) , 672-683
Differences in Safety Signal Detection between Osimertinib and First- and Second-Generation EGFR-TKIs: A Pharmacovigilance Study Using a Spontaneous Reporting System
Introduction: This study aimed to evaluate the trends in safety signal detection of osimertinib compared with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) through volcano plot analysis, using data from the Japanese Adverse Drug Event Report (JADER) and FDA Adverse Event Reporting System (FAERS). The overall objective of this study was to identify the potential risks associated with osimertinib-induced adverse events. Methods: Data were retrieved from the JADER (Q1 2004–Q1 2024) and FAERS (Q4 1997–Q2 2024) databases. The target drugs were osimertinib, gefitinib, erlotinib, and afatinib. Adverse event reports were standardized by converting all records in the database to the preferred terms of the International Classification of Diseases and subsequently mapping them to the high-level terms (HLTs) of the Medical Dictionary for Regulatory Activities. Volcano plots of odds ratios and z scores were generated to assess variations in detection trends between osimertinib and the abovementioned three EGFR-TKIs. The top 20 HLTs that demonstrated significant safety signals were computed and compared. Results: The numbers of safety signals detected in the JADER for osimertinib compared to the aforementioned EGFR-TKIs following volcano plot analysis were 24, 20, and 16, whereas detected safety signals were 7, 43, and 14 in FAERS. In the JADER database, the most frequently reported adverse reactions for osimertinib included “poisoning and toxicity” and “heart failure.” Conversely, in the FAERS database, the predominant adverse reactions were “death and sudden death” and “marrow depression and hypoplastic anemias.” Conclusion: This study confirmed an increased frequency of reports linking osimertinib to cardiotoxicity, bone marrow suppression, and anemia. However, interstitial pneumonia, previously considered a risk factor, was not identified. When evaluating risks influenced by racial and treatment-related factors, caution must be exercised regarding potential discrepancies between reported rates and true incidence.
- 25 September 2025
- Published by S. Karger AG in Oncology
- Vol. 104 (6) , 672-683
Differences in Safety Signal Detection between Osimertinib and First- and Second-Generation EGFR-TKIs: A Pharmacovigilance Study Using a Spontaneous Reporting System
Introduction: This study aimed to evaluate the trends in safety signal detection of osimertinib compared with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) through volcano plot analysis, using data from the Japanese Adverse Drug Event Report (JADER) and FDA Adverse Event Reporting System (FAERS). The overall objective of this study was to identify the potential risks associated with osimertinib-induced adverse events. Methods: Data were retrieved from the JADER (Q1 2004–Q1 2024) and FAERS (Q4 1997–Q2 2024) databases. The target drugs were osimertinib, gefitinib, erlotinib, and afatinib. Adverse event reports were standardized by converting all records in the database to the preferred terms of the International Classification of Diseases and subsequently mapping them to the high-level terms (HLTs) of the Medical Dictionary for Regulatory Activities. Volcano plots of odds ratios and z scores were generated to assess variations in detection trends between osimertinib and the abovementioned three EGFR-TKIs. The top 20 HLTs that demonstrated significant safety signals were computed and compared. Results: The numbers of safety signals detected in the JADER for osimertinib compared to the aforementioned EGFR-TKIs following volcano plot analysis were 24, 20, and 16, whereas detected safety signals were 7, 43, and 14 in FAERS. In the JADER database, the most frequently reported adverse reactions for osimertinib included “poisoning and toxicity” and “heart failure.” Conversely, in the FAERS database, the predominant adverse reactions were “death and sudden death” and “marrow depression and hypoplastic anemias.” Conclusion: This study confirmed an increased frequency of reports linking osimertinib to cardiotoxicity, bone marrow suppression, and anemia. However, interstitial pneumonia, previously considered a risk factor, was not identified. When evaluating risks influenced by racial and treatment-related factors, caution must be exercised regarding potential discrepancies between reported rates and true incidence.
- 14 September 2025
- Published by Wiley in Journal of Pineal Research
- Vol. 77 (5) , e70080
Sequence Symmetry Analysis of the Interrelationships Between Ramelteon and Parkinson's Disease
Parkinson's disease is the second most frequent neurodegenerative disease after Alzheimer's disease, and the most common neurodegenerative disease that causes movement dysfunction. Without innovations in prevention and treatment, the incidence and prevalence of Parkinson's disease is projected to increase by > 30% by 2030, making the development of new treatments an urgent priority. We previously investigated the association between melatonin receptor agonists and Parkinson's disease using the US Food and Drug Administration's Adverse Event Reporting System (FAERS). The results showed that ramelteon may reduce the incidence of Parkinson's disease. However, since the US FAERS relies on spontaneous reports, which are susceptible to reporting bias, further validation using real‐world data is required. This study investigated the association between ramelteon use and risk of developing Parkinson's disease using the DeSC database, a Japanese claims database reported to be representative of the general Japanese population. The association was evaluated using sequence symmetry analysis, with the adjusted sequence ratio (ASR) serving as the evaluation index. Our DeSC database analysis showed a negative association between ramelteon use and Parkinson's disease (ASR: 0.959, 95% confidence interval: 0.955–0.964). Our results support previous reports suggesting that ramelteon may help suppress the onset of Parkinson's disease. However, even though this study used real‐world data, these results should be interpreted with caution, as a sequence symmetry analysis cannot be adjusted for covariates. Therefore, additional pharmacoepidemiological studies are needed to further verify the potential risk of Parkinson's disease associated with ramelteon use.
- 14 September 2025
- Published by Wiley in Journal of Pineal Research
- Vol. 77 (5) , e70080
Sequence Symmetry Analysis of the Interrelationships Between Ramelteon and Parkinson's Disease
Parkinson's disease is the second most frequent neurodegenerative disease after Alzheimer's disease, and the most common neurodegenerative disease that causes movement dysfunction. Without innovations in prevention and treatment, the incidence and prevalence of Parkinson's disease is projected to increase by > 30% by 2030, making the development of new treatments an urgent priority. We previously investigated the association between melatonin receptor agonists and Parkinson's disease using the US Food and Drug Administration's Adverse Event Reporting System (FAERS). The results showed that ramelteon may reduce the incidence of Parkinson's disease. However, since the US FAERS relies on spontaneous reports, which are susceptible to reporting bias, further validation using real‐world data is required. This study investigated the association between ramelteon use and risk of developing Parkinson's disease using the DeSC database, a Japanese claims database reported to be representative of the general Japanese population. The association was evaluated using sequence symmetry analysis, with the adjusted sequence ratio (ASR) serving as the evaluation index. Our DeSC database analysis showed a negative association between ramelteon use and Parkinson's disease (ASR: 0.959, 95% confidence interval: 0.955–0.964). Our results support previous reports suggesting that ramelteon may help suppress the onset of Parkinson's disease. However, even though this study used real‐world data, these results should be interpreted with caution, as a sequence symmetry analysis cannot be adjusted for covariates. Therefore, additional pharmacoepidemiological studies are needed to further verify the potential risk of Parkinson's disease associated with ramelteon use.
- 29 May 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1873-1874
Comment on: ‘Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA adverse event reporting system database’
- 29 May 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1873-1874
Comment on: ‘Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA adverse event reporting system database’
- 14 May 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 385, 119411
Spontaneous reporting data cannot show that the risk of pancreatitis with quetiapine is about 30 times greater than with other drugs
- 14 May 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 385, 119411
Spontaneous reporting data cannot show that the risk of pancreatitis with quetiapine is about 30 times greater than with other drugs
- 1 May 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1873-1874
Comment on: ‘Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA adverse event reporting system database’
- 1 May 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (6) , 1873-1874
Comment on: ‘Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA adverse event reporting system database’